Compare Bristol-Myers Squibb Co (BMY) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nucor Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.87 (market cap $129.94B), while Nucor Corporation trades at $269.76 (market cap $61.93B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.1× Nucor Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | NUE | |
|---|---|---|
Market Cap | $129.94B | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $274.74 |
52-Week Low | $42.60 | $131.78 |
Enterprise Value | $163.92B | $66.34B |
Dividend Yield | 3.96% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Nucor (NUE) trades at $274.61, up 0.73% today, with a bullish technical outlook and strong earnings beats in Q1 and Q2 2026. The stock shows robust fundamentals with a P/E of 21.7 and net income margin of 7.99%, supported by record steel shipments and higher prices. Recent news highlights its position near buy points and resilience in industrial demand.
Outlook is positive with analyst consensus favoring buy ratings (59.37%) and a $279.63 price target. Risks include cyclical steel demand and tariff impacts, but earnings growth and institutional support provide upside potential for investors seeking exposure to industrial recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
